



Pharmaceuticals
Level 2, Generator @GridAKL
12 Madden Street, Auckland
New Zealand 1010

Tel +64 9 367 2900
Fax +64 9 367 2910
www.gsk.com | nz.gsk.com

14 March 2022

Dear Pharmacist,

Re: Seretide 50mcg/25mcg Inhaler (Fluticasone Propionate/Salmeterol) availability

GlaxoSmithKline New Zealand (GSK) wishes to inform you of expected stock out for Seretide 50mcg/25mcg (Fluticasone Propionate / Salmeterol) Inhaler (Pharmacode: **2120194**) due to increased demand and logistics issue causing delay in the incoming shipment.

GSK is working with PHARMAC to bring more stock into New Zealand as soon possible. The estimated time of arrival (ETA) is currently **mid-April 2022**.

Please find the summary table below:

Product Description	Pharmacode	Estimated time of resolution
Seretide 50mcg/25mcg Metered Dose Inhaler (MDI) (Fluticasone Propionate 50mcg / Salmeterol 25mcg)	2120194	Mid-April 2022

Updates will be made on the PHARMAC website once Seretide 50/25 inhaler is back in stock. We apologise for the inconvenience caused and we appreciate your support during this period.

Please do not hesitate to contact our customer support at mel.customersupport@gsk.com for any queries regarding supply of Seretide 50mcg/25mcg Inhaler.

Yours sincerely,

George Ham
Business Intelligence & Analytics Associate
GlaxoSmithKline NZ Limited

Seretide (fluticasone propionate/salmeterol xinafoate inhaler 50/25mcg per actuation, Prescription medicine) is indicated for the regular treatment of asthma (Reversible Obstructive Airways Disease) in adults, adolescents and children aged 4 years and over, where use of a combination product (bronchodilator and inhaled corticosteroid) is appropriate. Before prescribing *Seretide*, please review the data sheet for information on dosage, contraindications, precautions, interactions and adverse effects. The data sheet is on the Medsafe website at www.medsafe.govt.nz. **Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500.** GlaxoSmithKline NZ Limited, Auckland

Trade marks are owned by or licensed to the GSK group of companies. ©2022 GSK group of companies or its licensor.

TAPS DA2245GS-NP-NZ-FPS-LTR-220001

Date of Approval: 03 22. Date of Expiry: 03 24.

GlaxoSmithKline NZ Limited
Co. No. 1235481